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Letters to the Editoran inotropic agent after CPB. However,
we hope some of the questions may be
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Reply to the Editor:
We appreciate the interest of Haas and
Camphausen in our recently published trial
of triiodothyronine (T3) in neonatal heart
surgery.1 The points they raised are ad-
dressed below.
Our center, like many other centers per-
forming infant heart surgery in the United
States, routinely uses high-dose intrave-
nous loop and thiazide diuretics rather than
peritoneal dialysis to manage postoperative
fluid overload. We agree that the results of
our study cannot be generalized to patients
who are treated with peritoneal dialysis.
The inotrope score used in our study,
adapted from Wernovsky and associates,2
was determined by the use of dopamine,
dobutamine, milrinone, epinephrine, and
norepinephrine. The cumulative dose of
dopamine in particular did not differ be-
tween treatment groups during the first 5
days after the operation. Vasodilator use
506 The Journal of Thoracic and Cardiovawas also similar between treatment groups:
milrinone was used routinely in our pa-
tients, with no difference in cumulative
milrinone dose between treatment arms at
5 days. A single patient (randomized to the
T3 group) received nitroprusside; no pa-
tients received phenoxybenzamine. Amio-
darone was not used in any subject.
We planned our trial so that cardiac
output was one of two primary outcome
measures. The technique used (direct mea-
surement of oxygen consumption by real-
time gas exchange) provides an objective
determination of cardiac output in children
who are sedated, ventilated, and stable.3
During the study period, infants were
weaned from mechanical ventilation at in-
creasingly shorter times after surgery, ren-
dering this measurement infeasible at 48
hours after surgery in several subjects.
However, the proportion of patients in each
treatment group in whom this end point
could not be measured (9/22 in the T3
group and 5/20 in the placebo group) was
not statistically significant (P  .34).
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To the Editor:
I read with great interest the recently pub-
lished study by Fakler and associates1 in
the August 2005 issue of the Journal. They
found, in their investigation, a poor agree-
ment between the measured oxygen con-
sumption (VO2) and the VO2 estimated
using the formulas of Krovetz and Gold-
bloom2 and LaFarge and Miettinen.3 Ac-
cording to the Krovetz-Goldbloom for-
mula, the mean difference was 53 mL/
min/m2 and the limits of agreement were
95.5 and11.1 mL/min/m2 for the lower
and upper limits, respectively. Use of the
Krovetz-Goldbloom formula led to a sys-
tematic and significant overestimation in
VO2 values (P  .0001). However, a sig-
nificant correlation was shown between
measured and assumed VO2 values with
this formula (R .61; P .0001). Accord-
ing to the LaFarge-Miettinen formula, the
mean difference was 15.6 mL/min/m2
and the limits of agreement were 120.0
and 88.8 mL/min/m2 for the lower and
upper limits, respectively. A systematic
and significant overestimation was also re-
ported using the LaFarge-Miettinen for-
mula. A significant correlation was, how-
ever, indicated between measured and
assumed VO2 with this model (R  0.38;
P  .0037). I speculated that the reason
that the measured VO2 values were signif-
icantly different from the assumed VO2
using both Krovetz-Goldbloom and Lafarge-
Miettinen formulas was because of a meth-
odologic weakness in statistics and modeling.
As discussed by the authors, these dif-
ferences between measured VO2 and VO2
estimated by the formulas might be due to
a difference of population. I agree with this
statement, but more credible is the argu-
ment that these differences are explained
by the coefficients of these formulas
(Krovetz-Goldbloom formula: VO2  a ·
height b · weight c; Lafarge-Miettinen
formula: VO2  a=  b= · ln(age)  c= ·
heart rate for male subjects and VO2 
a= b · ln(age) c= · heart rate for female
subjects). These coefficients (a, b, c and a=,
b=, b and c=) depend on the characteristics
of the population included in the study.
That is why the use of published formulas
without any coefficient correction cannot
be applied in other populations, as shown
in another study.4 To overcome this prob-
lem, new formulas with new coefficients
should be calculated from the population
